Nurix Therapeutics(NRIX)
BRISBANE, CABiotechnology
Focus: Nurix is a public biotechnology company focused on small-molecule protein degradation therapeutics for oncology, with a clinical-stage pipeline spanning hematologic and solid tumors. The company is scaling toward commercialization with a Roche partnership on its lead program.
Profile data last refreshed 3h ago · AI intelligence enriched 8h ago
Funding Stage
PUBLIC
Open Jobs
21+5 this month
Growing — net +5 jobs in 30d
12 jobs added vs 7 removed. Steady team buildout.
Should You Work at Nurix Therapeutics?
AI assessmentStrong science and partnership momentum make Nurix attractive for oncology-focused scientists and regulatory professionals willing to tolerate near-term financing risk in exchange for upside in a niche modality.
Why Work Here
- Protein degradation is a high-conviction oncology modality with limited competitors; Nurix owns core IP and partnerships with Roche signaling validation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$77M
Pipeline & Clinical Trials
NX-5948
Healthy VolunteerClinical Trials (3)
NCT07516093Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Phase 3Help build intelligence for Nurix Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.